Achieve Life Sciences (ACHV) Depreciation & Amortization (CF) (2010 - 2026)
Achieve Life Sciences (ACHV) posted Depreciation & Amortization (CF) of $57000.0 for Q1 2026, little changed on a QoQ basis from $57000.0 in Q4 2025, and down 8.06% year-over-year from $62000.0 in Q1 2025.
Achieve Life Sciences (ACHV) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Achieve Life Sciences' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $57000.0 for Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 8.06% year-over-year to $57000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $223000.0 (down 4.7% YoY) and the FY2025 annual result came in at $228000.0, changed 0.44% from the prior year.
- Depreciation & Amortization (CF) was $57000.0 for Q1 2026 at Achieve Life Sciences, roughly flat from $57000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $65000.0 in Q4 2022 and bottomed at $54000.0 in Q3 2025.
- A 5-year average of $57529.4 and a median of $57000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) dropped 12.31% — and 2025, when it climbed 8.77%.
- Achieve Life Sciences' Depreciation & Amortization (CF) stood at $65000.0 in 2022, then fell by 12.31% to $57000.0 in 2023, then grew by 1.75% to $58000.0 in 2024, then retreated by 1.72% to $57000.0 in 2025, then changed by 0.0% to $57000.0 in 2026.
- Business Quant data shows ACHV's Depreciation & Amortization (CF) at $57000.0 in Q1 2026, $57000.0 in Q4 2025, and $54000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Achieve Life Sciences | 326.16 Mn | 326.16 Mn | - | 57,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 57,000.00 |
| Mar 31, 2026 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Dec 31, 2025 | 57,000.00 |
| Sep 30, 2025 | 54,000.00 |
| Sep 30, 2025 | 54,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Jun 30, 2025 | 55,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Mar 31, 2025 | 62,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Dec 31, 2024 | 58,000.00 |
| Sep 30, 2024 | 57,000.00 |
| Sep 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Jun 30, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Dec 31, 2023 | 57,000.00 |
| Dec 31, 2023 | 57,000.00 |